Literature DB >> 18047542

Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis.

Wulfran Cacheux1, Philippe Seksik, Marc Lemann, Philippe Marteau, Isabelle Nion-Larmurier, Pauline Afchain, Fady Daniel, Laurent Beaugerie, Jacques Cosnes.   

Abstract

OBJECTIVES: Cyclosporine is an effective rescue therapy in steroid-refractory ulcerative colitis (UC) and may avoid immediate colectomy. However, the individual's response to cyclosporine is poorly predictable. The aim of this study was to identify predictive factors of the response to cyclosporine in steroid-refractory UC.
METHODS: One hundred thirty-five patients with steroid-refractory UC, admitted consecutively between 1992 and 2004, were included. Data were collected on the first day of the cyclosporine therapy. Colonoscopy was performed within 2 days preceding or following the cyclosporine treatment in 118 patients for assessing the presence of severe endoscopic lesions.
RESULTS: The actuarial rate of colectomy was 0.45 at 6 months. Cox analysis in the whole population selected three predictive criteria of colectomy: body temperature >37.5 degrees C (adjusted hazard ratio = 1.94, 95% confidence interval 1.51-2.49), heart rate >90 bpm (1.86, 1.45-2.38), and C-reactive protein (CRP) >45 mg/L (1.70, 1.34-2.16). In the 118 patients who underwent colonoscopy, the presence of severe endoscopic lesions was an independent predictive factor of colectomy (2.38, 1.80-3.14). Colonoscopy was decisive and changed the therapeutic decision in patients with one or two criteria: 71% of the patients with severe endoscopic lesions were colectomized versus 17% of the patients without severe endoscopic lesions (P < 0.001). Finally, the clinical, biological, and endoscopic criteria allowed the classification of the patients into two different groups (80%vs 20% colectomy at 6 months).
CONCLUSION: In patients with steroid-refractory UC, the combination of simple criteria is useful to predict the response to cyclosporine. Colonoscopy is crucial in patients with intermediate clinical and biological severity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18047542     DOI: 10.1111/j.1572-0241.2007.01653.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  17 in total

1.  The role of mucosal healing in the treatment of patients with inflammatory bowel disease.

Authors:  Byron P Vaughn; Sveta Shah; Adam S Cheifetz
Journal:  Curr Treat Options Gastroenterol       Date:  2014-03

Review 2.  Optimizing conventional therapies for inflammatory bowel disease.

Authors:  Miles P Sparrow; Peter M Irving; Stephen B Hanauer
Journal:  Curr Gastroenterol Rep       Date:  2009-12

Review 3.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

4.  Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis.

Authors:  Taku Kobayashi; Makoto Naganuma; Susumu Okamoto; Tadakazu Hisamatsu; Nagamu Inoue; Hitoshi Ichikawa; Tetsuro Takayama; Riko Saito; Tomohisa Sujino; Haruhiko Ogata; Yasushi Iwao; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2010-07-08       Impact factor: 7.527

Review 5.  Biomarkers as potential treatment targets in inflammatory bowel disease: A systematic review.

Authors:  Travis Murdoch; Sarah O'Donnell; Mark S Silverberg; Remo Panaccione
Journal:  Can J Gastroenterol Hepatol       Date:  2015-05

Review 6.  Diagnostic advances in inflammatory bowel disease (imaging and laboratory).

Authors:  Maria E Moscandrew; Edward V Loftus
Journal:  Curr Gastroenterol Rep       Date:  2009-12

7.  Prognostic factors for colectomy in refractory ulcerative colitis treated with calcineurin inhibitors.

Authors:  Shigeki Bamba; Akira Andoh; Hirotsugu Imaeda; Hiromitsu Ban; Ayako Kobori; Yousuke Mochizuki; Makoto Shioya; Takashi Nishimura; Osamu Inatomi; Masaya Sasaki; Yasuharu Saitoh; Tomoyuki Tsujikawa; Yoshihide Fujiyama
Journal:  Exp Ther Med       Date:  2012-04-11       Impact factor: 2.447

8.  Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis.

Authors:  Ryan Nelson; Chuanhong Liao; Alessandro Fichera; David T Rubin; Joel Pekow
Journal:  Inflamm Bowel Dis       Date:  2014-01       Impact factor: 5.325

Review 9.  Steroid-refractory severe ulcerative colitis: what are the available treatment options?

Authors:  Alan C Moss; Mark A Peppercorn
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 10.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Authors:  L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.